S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
'War of the states': EV, chip makers lavished with subsidies
Where Are The Markets Going Next? (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
No more room for vroom? Paris votes on banishing e-scooters
Where Are The Markets Going Next? (Ad)pixel
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
'War of the states': EV, chip makers lavished with subsidies
Where Are The Markets Going Next? (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
No more room for vroom? Paris votes on banishing e-scooters
Where Are The Markets Going Next? (Ad)pixel
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
'War of the states': EV, chip makers lavished with subsidies
Where Are The Markets Going Next? (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
No more room for vroom? Paris votes on banishing e-scooters
Where Are The Markets Going Next? (Ad)pixel
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
'War of the states': EV, chip makers lavished with subsidies
Where Are The Markets Going Next? (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Shipbuilder Austal executives accused of inflating earnings
Where Are The Markets Going Next? (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
No more room for vroom? Paris votes on banishing e-scooters
Where Are The Markets Going Next? (Ad)pixel
NASDAQ:INSM

Insmed - INSM Stock Forecast, Price & News

$17.05
+0.29 (+1.73%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$16.74
$17.36
50-Day Range
$16.26
$21.73
52-Week Range
$16.04
$28.94
Volume
1.36 million shs
Average Volume
1.27 million shs
Market Capitalization
$2.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$43.33

Insmed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
154.2% Upside
$43.33 Price Target
Short Interest
Bearish
8.09% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.53mentions of Insmed in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$518,005 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.41) to ($3.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

132nd out of 996 stocks

Pharmaceutical Preparations Industry

54th out of 484 stocks


INSM stock logo

About Insmed (NASDAQ:INSM) Stock

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Stock News Headlines

Insmed (NASDAQ:INSM) Raised to "Hold" at StockNews.com
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
Insmed Full Year 2022 Earnings: EPS Misses Expectations
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
5 Hypergrowth Stocks to Buy Now
Luke Lango has found 14 stocks that have gone up over 1,000%. Now he’s named his top stocks for 2023. Just click to claim your copy. pixel
Insmed Stock (NASDAQ:INSM), Quotes and News Summary
Analyst Ratings for Insmed
Insmed To Present at the Nasdaq 47th Investor Conference
Insmed Director Trades Company's Stock
Insmed To Present at Three November Conferences
See More Headlines
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

INSM Company Calendar

Last Earnings
10/28/2021
Today
4/02/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$43.33
High Stock Price Forecast
$53.00
Low Stock Price Forecast
$28.00
Forecasted Upside/Downside
+154.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-481,530,000.00
Net Margins
-196.26%
Pretax Margin
-195.69%

Debt

Sales & Book Value

Annual Sales
$245.36 million
Book Value
$0.65 per share

Miscellaneous

Free Float
130,089,000
Market Cap
$2.33 billion
Optionable
Optionable
Beta
1.57

Social Links


Key Executives

  • Mr. William H. Lewis J.D. (Age 50)
    Pres, CEO & Chairman
  • Mr. Paolo Tombesi (Age 55)
    Chief Financial Officer
  • Ms. Christine A. Pellizzari J.D. (Age 51)
    Chief Legal Officer & Corp. Sec.
  • Mr. Roger  AdsettMr. Roger Adsett (Age 50)
    Chief Commercial Officer
  • Dr. Paul D. Streck (Age 55)
    Advisor













INSM Stock - Frequently Asked Questions

Should I buy or sell Insmed stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last twelve months. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings
or view top-rated stocks.

What is Insmed's stock price forecast for 2023?

11 brokers have issued twelve-month price targets for Insmed's shares. Their INSM share price forecasts range from $28.00 to $53.00. On average, they predict the company's share price to reach $43.33 in the next year. This suggests a possible upside of 154.2% from the stock's current price.
View analysts price targets for INSM
or view top-rated stocks among Wall Street analysts.

How have INSM shares performed in 2023?

Insmed's stock was trading at $19.98 on January 1st, 2023. Since then, INSM shares have decreased by 14.7% and is now trading at $17.05.
View the best growth stocks for 2023 here
.

Are investors shorting Insmed?

Insmed saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 11,040,000 shares, an increase of 6.0% from the February 28th total of 10,420,000 shares. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is presently 8.6 days.
View Insmed's Short Interest
.

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our INSM earnings forecast
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) posted its earnings results on Thursday, October, 28th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by $0.13. The biopharmaceutical company earned $46.80 million during the quarter, compared to analysts' expectations of $49.23 million. Insmed had a negative trailing twelve-month return on equity of 865.02% and a negative net margin of 196.26%. Insmed's revenue was up 6.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.63) earnings per share.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $17.05.

How much money does Insmed make?

Insmed (NASDAQ:INSM) has a market capitalization of $2.33 billion and generates $245.36 million in revenue each year. The biopharmaceutical company earns $-481,530,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.

How many employees does Insmed have?

The company employs 373 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The official website for the company is www.insmed.com. The biopharmaceutical company can be reached via phone at 908-977-9900, via email at investor.relations@insmed.com, or via fax at 732-438-0381.

This page (NASDAQ:INSM) was last updated on 4/2/2023 by MarketBeat.com Staff